Government's Commitment To Healthcare To Boost China's Clinical Trial Sector

BMI View: China's huge population of drug-naïve patients, coupled with the increasingly ageing population (and hence increasing burden from non-communicable diseases), will generate a leading centre for clinical trials, especially in the areas of cardiovascular disease, cancer and diabetes. We highlight the country's increased adherence to global clinical trials regulations as a positive development for clinical trials companies, but note that its longer approval time for studies and language barrier present hurdles to sector

To read the full article, please choose one of the following options: